NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumor|Ovarian Cancer|Ovary Cancer|Cancer of Ovary|Cancer of the Ovary|Ovary Neoplasm|Pancreatic Cancer|Pancreas Cancer|Cancer of Pancreas|Cancer of the Pancreas|Pancreas Neoplasm|Prostate Cancer|Prostatic Cancer|Cancer of Prostate|Cancer of the Prostate|Prostate Neoplasm|Castrate Resistant Prostate Cancer|Castration Resistant Prostatic Cancer|Castration Resistant Prostatic Neoplasms|Triple-negative Breast Cancer|Triple Negative Breast Cancer|Triple Negative Breast Neoplasms|Breast Cancer|Breast Carcinoma|Cancer of Breast|Cancer of the Breast|Breast Tumor
Interventions: DRUG: NUV-868|DRUG: Olaparib|DRUG: Enzalutamide
Sponsor: Nuvation Bio Inc.